Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation..

阿拉巴马州伯明翰市的维韦克·拉尔博士创立的先锋呼吸药物开发生物技术公司Alveolus Bio宣布了一轮由知名全球制药公司Shilpa Medicare Limited（BSE：524742）（NSE：SHILPAMED）主导的战略融资，该公司在呼吸治疗制造和生物技术创新方面拥有广泛的专业知识。

Through this collaboration, Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development and manufacturing partner. This partnership propels Alveolus Bio's live biotherapeutics and small molecule platform towards Phase 2 and first-in-human clinical trials, with a lead asset for COPD progressing rapidly..

通过此次合作，Shilpa Medicare的生物制品部门Shilpa Biologics将成为Alveolus Bio全球独家的开发和制造合作伙伴。这一合作将推动Alveolus Bio的活体生物治疗和小分子平台进入二期临床试验和首次人体试验，其针对慢性阻塞性肺病（COPD）的主要资产正在快速推进。

Shilpa Medicare brings deep experience in drug discovery, development, and manufacturing, along with strong regulatory capabilities. Their investment and strategic involvement will accelerate the clinical advancement of Alveolus Bio's resMIT (respiratory microbiota-based inhaled therapeutics) platform.

Shilpa Medicare在药物发现、开发和制造方面拥有深厚的经验，并具备强大的监管能力。他们的投资和战略参与将加速Alveolus Bio的resMIT（基于呼吸道微生物群的吸入疗法）平台的临床进展。

This novel platform enables targeted delivery of inhaled therapies to deep lung regions, addressing unmet needs in diseases such as COPD, Bronchopulmonary Dysplasia (BPD), and Pulmonary Fibrosis..

该新型平台能够将吸入疗法靶向递送至肺部深处，满足了慢性阻塞性肺病 (COPD)、支气管肺发育不良 (BPD) 和肺纤维化等疾病未被满足的需求。

'Securing Shilpa as our lead investor is a transformative step,' said Gaurav Mehta, CEO of Alveolus Bio. 'Their global pharmaceutical leadership aligns perfectly with our vision to redefine how lung diseases are treated.'

“确保Shilpa成为我们的主要投资者是一个变革性的步骤，”Alveolus Bio首席执行官Gaurav Mehta表示，“他们在全球制药领域的领导地位与我们重新定义肺部疾病治疗方法的愿景完美契合。”

'Alveolus Bio's breakthrough science is poised to transform respiratory care. Through this strategic partnership with Shilpa, we combine disruptive biotech innovation with world-class commercialization, bringing life-changing therapies faster to the market,' said Dr. C. Vivek Lal, Founder and CSO, Alveolus Bio..

阿尔维奥生物的突破性科学有望变革呼吸系统护理。通过与希帕的战略合作，我们将颠覆性的生物技术创新与世界级的商业化能力相结合，更快地将改变生命的疗法推向市场，”阿尔维奥生物创始人兼首席科学官C. Vivek Lal博士表示。

'Shilpa has always focused on enabling breakthrough biologics,' said Vishnukant Bhutada, Managing Director, Shilpa Medicare. 'This partnership strengthens our innovation pipeline and reinforces our role as a trusted global partner for biotech development.'

“Shilpa始终专注于推动突破性生物制品的发展，”Shilpa Medicare董事总经理Vishnukant Bhutada表示，“此次合作加强了我们的创新研发管线，并巩固了我们作为生物技术开发领域值得信赖的全球合作伙伴的地位。”

The financing round remains open to other strategic investors who share Alveolus Bio's vision of transforming respiratory medicine.

本轮融资仍对其他与Alveolus Bio拥有相同愿景、致力于转变呼吸医学的战略投资者开放。

About Shilpa Medicare

关于Shilpa医保

Shilpa Medicare is a global pharmaceutical company with capabilities across drug discovery to commercialization, specializing in respiratory therapeutics and biotech innovation. Visit www.vbshilpa.com.

Shilpa Medicare 是一家全球性的制药公司，业务范围涵盖从药物发现到商业化的全过程，专注于呼吸系统治疗和生物技术创新。访问 www.vbshilpa.com。

About Alveolus Bio

关于Alveolus Bio

A Biostack Ventures company, Alveolus Bio is developing first-in-class therapies for lung diseases using its proprietary resMIT platform. Its pipeline includes programs for COPD, BPD, Pulmonary Fibrosis, Cystic Fibrosis, and more.

生物栈风险投资公司 Alveolus Bio 正在利用其专有的 resMIT 平台开发针对肺部疾病的首创疗法。其研发管线包括慢性阻塞性肺病、支气管肺发育不良、肺纤维化、囊性纤维化等项目。

Source: prnewswire.com

来源：prnewswire.com